Current treatment options include: * Surgical debulking * High-dose corticosteroid therapy * Ciclosporin * Interferon-α * Chemotherapy * Vemurafenib. It would appear that approximately half these patients harbor point mutations of the BRAF gene at codon 600 substituting the amino acid glutamine for valine. Vemurafenib, an oral FDA approved targeted agent to the BRAF protein for melanoma, shows dramatic activity in patients<unk>  whose tumor contains the same mutation. In 2017 the US FDA approved vemurafenib for this indication. * Radiation therapy All current treatments have had varying degrees of success. The vinca alkaloids and anthracyclines have been used most commonly in ECD treatment.
Erdheim–Chester disease
Winchester syndrome
Copenhagen disease
Juvenile idiopathic arthritis
Calcium pyrophosphate dihydrate crystal deposition disease
Rheumatoid nodulosis
Secondary systemic amyloidosis
Reactive arthritis